158 related articles for article (PubMed ID: 6556949)
1. Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity.
Hansson Y; Paulie S; Larsson A; Lundblad ML; Perlmann P; Näslund I
Cancer Immunol Immunother; 1983; 16(1):23-9. PubMed ID: 6556949
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls.
Troye M; Hansson Y; Paulie S; Perlmann P; Blomgren H; Johansson B
Int J Cancer; 1980 Jan; 25(1):45-51. PubMed ID: 7399744
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures.
Troye M; Vilien M; Pape GR; Perlmann P
Int J Cancer; 1980 Jan; 25(1):33-43. PubMed ID: 7399743
[TBL] [Abstract][Full Text] [Related]
4. Membrane-associated antigens on tumor cells from transitional-cell carcinoma of the human urinary bladder. I. Immunological characterization by xenogeneic antisera.
Schneider MU; Troye M; Paulie S; Perlmann P
Int J Cancer; 1980 Aug; 26(2):185-92. PubMed ID: 7203712
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral in vitro cytotoxicity against autologous bladder tumor cells in humans. Differences in autologous cytotoxicity against non-invasive and invasive transitional-cell tumors of the urinary bladder.
Jacobsen F
Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):235-9. PubMed ID: 7315359
[TBL] [Abstract][Full Text] [Related]
6. Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary.
Perlmann P; Troye M; Pape G; Blomgren H; Johansson B
Urol Res; 1978; 6(4):207-9. PubMed ID: 741533
[TBL] [Abstract][Full Text] [Related]
7. Production of antibodies to cellular antigens by EBV-transformed lymphocytes from patients with urinary bladder carcinoma.
Paulie S; Lundblad ML; Hansson Y; Koho H; Ben-Aissa H; Perlmann P
Scand J Immunol; 1984 Nov; 20(5):461-70. PubMed ID: 6095441
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma.
Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE
J Urol; 1975 May; 113(5):663-7. PubMed ID: 1168732
[TBL] [Abstract][Full Text] [Related]
9. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
Moroz C; Madgar I; Twig S; Lindner A; Many M
Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847
[TBL] [Abstract][Full Text] [Related]
10. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
Mai KT; Yazdi HM; Farmer J
Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated cytotoxicity against human bladder cancer.
Bloom ET; Ossorio RC; Brosman SA
Int J Cancer; 1974 Sep; 14(3):326-34. PubMed ID: 4477556
[No Abstract] [Full Text] [Related]
12. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
13. A follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity.
Larsson A; Näslund I; Troye M
Cancer Immunol Immunother; 1982; 14(2):82-5. PubMed ID: 6965230
[TBL] [Abstract][Full Text] [Related]
14. A 51chromium isotope release assay for detecting cytotoxicity to human bladder carcinoma.
O'Toole C
Int J Cancer; 1977 Mar; 19(3):324-31. PubMed ID: 844912
[TBL] [Abstract][Full Text] [Related]
15. Serum induced lymphoid cell mediated cytotoxicity to human transitional cell carcinomas of the genitourinary tract.
Hakala TR; Lange PH
Science; 1974 May; 184(4138):795-7. PubMed ID: 4856602
[TBL] [Abstract][Full Text] [Related]
16. MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma (TCC) of the urinary bladder.
Hansson Y; Vargas-Cortes M; Paulie S; Perlmann P
Cancer Immunol Immunother; 1988; 27(3):205-12. PubMed ID: 3263206
[TBL] [Abstract][Full Text] [Related]
17. An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder.
Ardelt PU; Ebbing J; Adams F; Reiss C; Arap W; Pasqualini R; Bachmann A; Wetterauer U; Riedmiller H; Kneitz B
PLoS One; 2015; 10(3):e0118646. PubMed ID: 25742283
[TBL] [Abstract][Full Text] [Related]
18. Plasma membrane-associated antigens on tumor cells derived from transitional-cell carcinoma of the human urinary bladder. II. Identification at the molecular level of plasma membrane-associated antigens.
Schneider MU; Paulie S; Troye M; Perlmann P
Int J Cancer; 1980 Aug; 26(2):193-202. PubMed ID: 7203713
[TBL] [Abstract][Full Text] [Related]
19. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.
Tyler DS; Stanley SD; Nastala CA; Austin AA; Bartlett JA; Stine KC; Lyerly HK; Bolognesi DP; Weinhold KJ
J Immunol; 1990 May; 144(9):3375-84. PubMed ID: 2329275
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunity to transitional cell carcinoma of the urinary bladder. III. Effects of hydrostatic pressure therapy.
O'Toole C; Helmstein K; Perlmann P; Moberger G
Int J Cancer; 1975 Sep; 16(3):413-26. PubMed ID: 1176202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
